Skip to Content

DB289 Approval Status

  • FDA approved: No
  • Brand name: DB289
  • Generic name: pafuramidine
  • Company: Immtech Pharmaceuticals, Inc.
  • Treatment for: Pneumocystis Pneumonia

DB289 (pafuramidine) is an investigational drug intended for use in the treatment of pneumocystis pneumonia.

In November 2006, Immtech Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation for pafuramidine (DB289) to treat Pneumocystis jiroveci pneumonia (PCP), a common life-threatening opportunistic infection in HIV/AIDS and other immunosuppressed patients.

Development Status and FDA Approval Process for DB289

Nov 21, 2006US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.